CurrentBlue Cross Blue Shield - MassachusettsPolicy 171

Lyme disease testing and treatment (coverage criteria)

Coverage and medical necessity criteria for diagnostic testing and antibiotic treatment of Lyme disease for Blue Cross Blue Shield - Massachusetts members across commercial and Medicare products.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyLyme disease testing and treatment (coverage criteria)

Policy CodePolicy 171

Change TypeNo material change noted

Effective DateN/A

Next Review DateN/A

Key ActionOrdering provider must attest the member has Lyme disease via confirmatory testing or clinical presentation before initiating therapy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2-4 weeksTypical IV duration

<14 daysCSF PCR window

5 codesCovered CPTs (when criteria met)

5 codesInvestigational CPTs

2-tieredRecommended serology

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Evidence for CXCL13/OspA/genotyping

Coverage and Medical Necessity Criteria

Medically Necessary Uses

Covered when ALL of the following are met

PCR CSF testing indication: PCR-based direct detection of B. burgdorferi in cerebrospinal fluid may be medically necessary and may replace serologic documentation in individuals with a short duration of neurologic symptoms.<14 days

PCR may be useful during the window before intrathecal or serum antibodies are detectable; intrathecal antibody production is generally more sensitive outside this early window.

Investigational Uses / Not Medically Necessary

Investigational / Not medically necessary when any of the following apply

Investigational PCR repeat or monitoring: Repeat PCR-based direct detection of B. burgdorferi is investigational when used to justify continuation of IV antibiotics beyond 1 month or to follow therapeutic response.

Repeat PCR should not be used to extend IV therapy or to monitor treatment response.

Investigational sample types and testing: PCR-based detection of B. burgdorferi in urine, genotyping/phenotyping of B. burgdorferi subspecies, stand-alone C6 peptide assays, CXCL13 chemokine testing, and Borrelia OspA antigen testing are investigational or have insufficient evidence to demonstrate improved net health outcomes.insufficient evidence

Specific novel immunoassay/immunoblot CPT codes are listed as investigational.

Coverage criteria for diagnostic testing and antibiotic therapy

Covered and investigational diagnostic approaches with logic tied to clinical context

Standard serologic testing: Use a screening ELISA (IgM, IgG, or combined) with confirmation by Western immunoblot or a second EIA; a positive or indeterminate ELISA alone is inadequate and results must be correlated with the clinical picture.2-tiered testing

C6 ELISA is sensitive but should be integrated into a 2-tiered strategy rather than used as a stand-alone confirmatory test.

PCR utility: PCR directly detects B. burgdorferi DNA and may be useful for skin biopsy specimens (erythema migrans), synovial tissue/fluid for Lyme arthritis, and cerebrospinal fluid early in neuroborreliosis; PCR is not recommended for urine or blood generally.time-sensitive for CSF (<14 days)

PCR has high contamination risk and cannot distinguish live from dead organisms; best detection for skin biopsies and synovial tissue.

Tests considered investigational or insufficient evidence:

PCR-based direct detection of Borrelia burgdorferi in urine samples is considered investigational in all clinical situations and is not supported as a routine diagnostic method. The policy specifically notes PCR on CSF may be medically necessary in a narrow early window for neurologic disease (<14 days), but extends an investigational stance to urine-based PCR and to repeat PCR when used to justify prolonged IV therapy or to monitor treatment response.

Several novel immunoassay/immunoblot CPT codes (listed as investigational) relate to emerging assays for Borrelia detection or characterization; these tests are not considered standard of care and are listed in the policy as investigational for Commercial and Medicare members.

Stand-alone C6 peptide assays, measurement of the CXCL13 chemokine, Borrelia Outer surface protein A (OspA) antigen testing, and genotyping/phenotyping of B. burgdorferi are described in the evidence summary as having insufficient evidence to demonstrate improved net health outcomes and are therefore considered investigational/insufficient for routine coverage.

The policy cites cohort studies, meta-analyses, and limited prospective data that show variable performance characteristics (for example, threshold variability for CXCL13 and limited cohort evidence for OspA), and states that additional research is needed before these assays can be recommended for standard clinical management.

The provided reference and endnote excerpts do not contain explicit exclusion statements that single out specific coverage denials beyond the investigational and not medically necessary positions documented elsewhere in the policy. References and guidance documents are listed but no separate, explicit coverage-exclusion language appears in these chunks.

Repeat PCR-based direct detection of B. burgdorferi performed to justify continuation of IV antibiotics beyond one month or to monitor therapeutic response is explicitly labeled investigational and therefore not medically necessary. The policy highlights limited utility of repeat PCR for monitoring and the lack of evidence supporting PCR-guided extension of IV therapy.

Limitations noted include low yield outside specific specimen types (CSF or synovial fluid early in disease), inability of PCR to distinguish live from dead organisms, and lack of data that repeat PCR improves patient outcomes or guides beneficial changes in management.

Randomized controlled trials and systematic reviews summarized in the policy have not demonstrated benefit from prolonged or repeated courses of oral or IV antibiotics (>4 weeks) for confirmed Lyme disease. Consequently, such prolonged or repeated antibiotic regimens are considered not medically necessary and investigational when used beyond the typical treatment durations.

The policy reinforces that oral therapy is usually adequate and that IV therapy, when used, is typically limited to a 2–4 week course for specific indications (for example, central nervous system or cardiac involvement), with evidence not supporting longer or repeated courses.

Within the provided excerpted reference material there are no explicit statements formatted as standalone 'not medically necessary' declarations beyond the investigational and not medically necessary positions documented within the testing and treatment sections. The references list trials and guideline documents that support the policy conclusions but do not add separate exclusion language in these chunks.

Coding and Billing

Covered CPT Codes (when medical necessity criteria met)CPTCovered

86617	Borrelia burgdorferi (Lyme disease) confirmatory test (e.g., Western blot or immunoblot).
86618	Antibody; Borrelia burgdorferi (Lyme disease).
86619	Antibody; Borrelia (relapsing fever).
87475	Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, direct probe technique.
87476	Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, amplified probe technique.

Investigational CPT CodesCPTNot Covered

0041U	Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM.
0042U	Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG.
0316U	Borrelia burgdorferi (Lyme disease), OspA protein evaluation, urine.
0580U	Borrelia burgdorferi, antibody detection of 24 recombinant protein groups, by immunoassay, IgG.
0615U	Borrelia burgdorferi (Lyme disease), antibody detection of 26 recombinant protein groups, by immunoassay, IgM.

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization summary: Inpatient precertification/preauthorization IS REQUIRED for services described in this policy when performed inpatient. Outpatient prior authorization is generally not required across commercial and Medicare product lines (Commercial Managed Care HMO/POS, Commercial PPO/Indemnity, Medicare HMO Blue, Medicare PPO Blue).

Inpatient: precertification/preauthorization required for all products when performed inpatient.
Outpatient: prior authorization not required for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue, and Medicare PPO Blue.

Prior Authorization

IV Antibiotic Prior Authorization Clarification

IV antibiotic prior authorization clarification: Policy history and statements clarify that short-term IV antibiotic use (2–4 weeks) for treatment of Lyme disease is considered medically necessary when ordered by a provider who attests to diagnosis by confirmatory testing or clinical presentation. The policy history notes prior clarifications that prior authorization for IV therapy is not required for outpatient settings; however, inpatient procedures still require precertification.

Background

Lyme disease is a multisystem infection caused primarily by Borrelia burgdorferi transmitted by Ixodes ticks. Clinical presentation ranges from localized early infection—classically an erythema migrans rash—to disseminated and late manifestations including neurologic disease, carditis (eg, atrioventricular block), and arthritis. Diagnosis is predominantly clinical and serologic; PCR can detect B. burgdorferi DNA in specimen types such as CSF or synovial fluid but has limited sensitivity and is useful only in specific niche indications (for example, early neuroborreliosis within 14 days), while intrathecal antibody production is generally more sensitive for neuroborreliosis.

Definitions and Key Terms

Long-term antibiotic therapy — definition

DefinitionAdministration of oral, intramuscular, or intravenous antibiotics singly or in combination for periods in excess of 4 weeks (per Massachusetts Chapter 183, Section 12DD).

PurposePrescribed to eliminate infection or to control a patient's symptoms upon clinical diagnosis of Lyme disease by a licensed physician.

Documentation requirementClinical diagnosis and treatment must be documented in the patient's medical record by the prescribing licensed physician.

Erythema migrans — clinical diagnosis

TermErythema migrans

Clinical significanceLocalized characteristic skin lesion of early Lyme disease; its presence can support a clinical diagnosis without immediate laboratory confirmation.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyLyme disease testing and treatment (coverage criteria)

Policy CodePolicy 171

Change TypeNo material change noted

Effective DateN/A

Next Review DateN/A

Key ActionOrdering provider must attest the member has Lyme disease via confirmatory testing or clinical presentation before initiating therapy.

SourceLink

On This Page

T-cell proliferative assays, CXCL13 concentration testing, Borrelia OspA antigen urine testing, genotyping/phenotyping of B. burgdorferi subspecies, and stand-alone C6 peptide assays lack sufficient evidence to demonstrate improved net health outcomes and are considered investigational.

insufficient evidence

Variability in thresholds (eg, CXCL13) and limited cohort data (eg, OspA) limit clinical utility.

Treatment duration limits: Oral antibiotics are usually adequate; IV antibiotics (eg, ceftriaxone) for CNS or peripheral neurologic involvement, heart block, or Lyme arthritis unresponsive to oral therapy may be indicated for a typical course of 2-4 weeks. Prolonged or repeated courses (>4 weeks) have not demonstrated benefit and are not supported.2-4 weeks typical IV course; >4 weeks not supported

Lack of benefit from prolonged courses suggests alternative explanations (eg, incorrect diagnosis or slow symptom resolution) rather than persistent infection.

Short-term IV antibiotics (2–4 weeks) are considered medically necessary when the ordering provider attests to Lyme disease by testing or clinical presentation.
Policy history (10/22/2019) clarified that prior authorization for IV therapy is not required when outpatient.
Inpatient IV therapy remains subject to precertification.

Note

Other Prior Authorization Requirements

Prior authorization — not specified: No additional or special prior authorization rules are specified elsewhere in these excerpts beyond the inpatient precertification requirement and the outpatient guidance above.

No other procedure- or code-specific prior authorization requirements are specified in the provided excerpts.

Documentation Required

Outpatient IV Therapy Documentation

Outpatient IV therapy documentation: For outpatient IV therapy, providers are required to complete the Home Infusion Therapy Prior Authorization Form #430. The ordering provider must also attest that the member has Lyme disease through confirmatory testing or based on the patient's clinical presentation when ordering short-term IV antibiotics.

Complete Home Infusion Therapy Prior Authorization Form #430 for outpatient IV therapy.
Provider attestation of diagnosis or clinical presentation required for short-term IV antibiotic orders.

Denial Risk

Denial Risk — Unnecessary or Nonrecommended Testing

Inappropriate or unnecessary testing may be denied: Diagnostic testing may not be necessary when a clinical diagnosis is sufficient (for example, erythema migrans). Two-tiered serologic testing (ELISA followed by Western immunoblot) is the recommended approach when testing is indicated; use of unproven or non-recommended assays may be considered investigational or denied.

Do not order serologic testing when clinical diagnosis (e.g., erythema migrans) is adequate.
When laboratory testing is indicated, use recommended 2-tiered testing (ELISA followed by Western immunoblot).
Unproven assays or nonrecommended tests may be denied.

Note

State Mandate — Chapter 183 (MA)

State mandate reference: Per Massachusetts Chapter 183 of the Acts of 2016 (An Act Relative to Long-Term Antibiotic Therapy for the Treatment of Lyme Disease), insurers must provide coverage for long-term antibiotic therapy when determined medically necessary and ordered by a licensed physician after thorough evaluation. The policy notes the statute and defines long-term antibiotic therapy as administration of antibiotics for periods in excess of 4 weeks.

Reference: Chapter 183 of the Acts of 2016 (Section 12DD).
Defines long-term antibiotic therapy as antibiotic administration >4 weeks and requires coverage when medically necessary and properly ordered.

Documentation Required

Documentation — Additional Notes

Documentation — none specified in excerpts: Aside from the specific attestation requirement by the ordering provider (diagnosis via confirmatory testing or clinical presentation) and the Home Infusion Therapy Prior Authorization Form #430 for outpatient IV therapy, no other documentation requirements are specified in the provided excerpts.

Ordering provider must attest to Lyme disease diagnosis by confirmatory testing or clinical presentation.
Home Infusion Therapy Prior Authorization Form #430 required for outpatient IV therapy.
No additional documentation rules are specified in these excerpts.

Diagnostic implicationDiagnosis may be made clinically based on history and physical exam; testing should be used as supportive data when indicated.

CDC immunoblot criteria

CDC immunoblot criteriaPositive if 2 of the 3 most common IgM antibody bands are present, or 5 of the 10 most frequent IgG antibody bands are present.

UseUsed to confirm serologic diagnosis in patients with positive or indeterminate ELISA tests.

LimitationsCDC criteria were developed for surveillance and are conservative; they may miss true cases and differ from European interpretation standards.

References and guidance

Key guideline and trialsRandomized and controlled trials of antibiotic duration and retreatment (eg, Berende et al. 2016; Klempner et al. 2001; Fallon et al. 2008) are cited to inform treatment recommendations.

Practice guidancePractice parameter and guideline documents (eg, AAN practice parameter, NICE guidance NG95) are referenced for neurologic and general management.

Reporting guidanceAssociation of Public Health Laboratories reporting language for serologic test interpretation is cited as a resource for laboratory result interpretation.

Additional evidenceSystematic reviews and evidence assessments (eg, Lantos et al. 2014; Cameron et al. 2014) are included to support statements about investigational tests and lack of benefit from prolonged antibiotics.